Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors

PURPOSE: There are few effective therapies for pancreatic neuroendocrine tumors (PNETs). Recent placebo-controlled phase III trials of the mammalian target of rapamycin (mTOR) inhibitor everolimus and the vascular endothelial growth factor (VEGF)/platelet-derived growth factor receptor inhibitor sun...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Clin Oncol
Prif Awduron: Hobday, Timothy J., Qin, Rui, Reidy-Lagunes, Diane, Moore, Malcolm J., Strosberg, Jonathan, Kaubisch, Andreas, Shah, Manisha, Kindler, Hedy Lee, Lenz, Heinz-Josef, Chen, Helen, Erlichman, Charles
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Clinical Oncology 2015
Pynciau:
ORIGINAL REPORTS
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4417726/
https://ncbi.nlm.nih.gov/pubmed/25488966
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.56.2082
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg